Log In
Print this Print this

Filgrastim NK, biosimilar filgrastim (formerly TKN732)

  Manage Alerts
Collapse Summary General Information
Company Teva Pharmaceutical Industries Ltd.
DescriptionA biosimilar of G-CSF
Molecular Target
Mechanism of ActionBiosimilar
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentApproved
Standard IndicationNeutropenia
Indication DetailsPrevent chemotherapy-induced neutropenia; Treat chemotherapy induced neutropenia
Regulatory Designation
PartnerNippon Kayaku Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today